· Over 20 US/EU cell therapy suites
· 300 employees
· US logistics hub for North America
Our 80,000+ square feet commercial-scale cGMP Compliant Manufacturing Facility in Memphis, TN, is within 10 minutes of the FedEx SuperHub, capable of servicing North America, South America, and Europe within 24 hours. Our world-class team of experts across all departments are able to leverage our commercial capacity for autologous and allogeneic cell and cell-mediated gene therapies. We have unparalleled experience in regenerative medicine, cell and gene immunotherapy fields, a diverse range of cell types and therapies, including but not limited to: CAR-T, TCR, MIL, DC, NK cell, MSC, hUC-MSC’s, gene-edited cells, and others.
We offer three suite configurations for our clients’ scalable needs:
Our Memphis facility is located near several life science facilities, the University of Tennessee, and St. Jude Children’s Research Hospital. Our proximity to the North American distribution hub ensures drop-off of patient material in the evening and delivery anywhere in North America by the next morning and enables support of shipment to and from North America, South America, and Europe within a 24-hour window.
4600 East Shelby Drive
Suite 108
Memphis, TN 38118
p: 901.541.9800
f: 443.451.8211
· Over 15 PD/AD staff
· Adjacent to BWI
· Life Science hub of Northeast Corridor
Located near Baltimore Washington International Airport is Cognate’s GLP laboratory facility containing our growing team of process and assay development experts, as well as a team focused on efficient technology transfer of the work performed in Baltimore into our GMP manufacturing units in Memphis. Our facility is geographically situated in Baltimore because of longstanding relationships with NIH, John’s Hopkins and the University of Maryland Medical Center as well as various biotechnology companies in the Eastern corridor.
2600 Cabover Drive
Suites E, F, G, & H
Hanover, MD 21076
Our Cobra Biologics International Centre of Excellence for ATMP Production, based on Keele Science Park in the UK, is dedicated to providing contract development and manufacturing services for both DNA and Viral Vectors from pre-clinical to clinical and commercial supply. With the Keele site founded in 1992 as a gene therapy company, and with 20+ years’ experience as a CDMO, Cobra has a unique knowledge base as both manufacturer and service provider for the global life sciences market.
Centre of Excellence for ATMP Production - DNA and Viral Vectors
Cobra Biologics
Stephenson Building
Keele Science Park
ST5 5SP UK
t: +44 (0)1782 714181
Our international Centre of Excellence for ATMP Production, based in Matfors, Sweden, specializes in contract development and manufacturing services for DNA and Microbiota. As part of the Cobra group since 2011, and with an extensive history dating back to the 1960s, our Matfors site extends a comprehensive service offering from concept through to fill and finish.
Centre of Excellence for ATMP Production - DNA and Microbiota
Cobra Biologics
Storjordenvägen 2
SE-864 31 Matfors
Sweden
t: +46 (0)60 7858 6001
Cognate operates commercial-scale cGMP-compliant Cell Therapy Manufacturing Facilities in Memphis, TN, within 10 minutes of the FedExWorld Hub capable of servicing North America, South America and Europe.
We know what it takes to get drugs from concept to approval. More importantly, we have the right experience, processes, and systems in place to enable a client to successfully transition from clinical development into commercial approvals, regardless of geography and regulatory environment.
Cognate operates an 80,000+ square feet commercial scale cGMP compliant manufacturing facility in Memphis, TN, within 10minutes of the FedEx World Hub capable of servicing North and South America and Europe.
Cognate can facilitate commercial scale production from Memphis, TN or anywhere in the world with a dedicated capacity configuration. Ask us how we can collaborate to bring lifesaving products closer to your patients.
We understand that the process of manufacturing begins with collection of starting material and ends with the patient, whether it’s allogeneic donors, or autologous patient-specific products.
Start to finish, we ensure the highest quality and safety of your product. The development, manufacturing and use of cell and cell-mediated gene therapy products involve quite a few ancillary services spanning testing, shipping, storage, logistics, primary tissue sourcing, scheduling and tracking among others.
Cognate can handle internally, or via a third party, all product characterization and release testing needs for cellular products. We have rapid release testing services, something that is critical with personalized therapies for fast turnaround.
Cognate has unparalleled experience in the large-scale manufacturing of both autologous and allogeneic cellular immunotherapy products that utilize cell and cell-mediated gene therapy technology.
Our experience in the development and manufacturing of drugs in the cellular immunotherapy space is unparalleled. For example, Cognate’s largest clinical-grade production to-date was for an autologous dendritic cell vaccine product and associated placebo that was used in a large phase III clinical trial. The starting materials (tumor and leukapheresis) and final product came from and shipped to more than 80 clinical sites in 4 countries.
Cognate offers a comprehensive range of analytical and process development solutions. With expertise in routine and customized analytical methods and process optimization we can help you reach your goals quickly and cost effectively.
Our High Quality (HQ) offering adopts features of Cobra’s GMP manufacture, including RNase free, with a 6 week delivery time. HQ plasmid can be used as an ancillary or starting material for the clinical manufacture of immuno-oncology therapies, for example in AAV, lentiviral vector and CRISPR products.
Cognate’s Cobra – Keele teams develop robust and scalable process strategies for viral vector manufacturing and production for AAV, lenti viral vectors and adenoviruses, with media development and optimization (animal component free) for both adherent and suspension modalities.
Our High Quality (HQ) offering adopts features of Cobra’s GMP manufacture, including RNase free, with a 6 week delivery time. HQ plasmid can be used as an ancillary or starting material for the clinical manufacture of immuno-oncology therapies, for example in AAV, lentiviral vector and CRISPR products.
Let's talk about how Cognate, the premier global leader in cell & gene therapy, will accelerate your product development & manufacturing efforts.